Highlights
- Zydus Lifesciences shares gained over 1% and touched a fresh 52-week high on July 8.
- The stock has outperformed the Nifty Next 50 across one-week, one-month and one-year periods.
- The company reported March 2026 standalone and consolidated quarterly financial results in May.
Zydus Lifesciences Ltd. (NSE:ZYDUSLIFE) traded higher during the morning session on July 8, with the stock advancing 1.26% to INR 1,167.50 as of 9:51 AM IST.
The stock opened at INR 1,146.60 and slipped to an intraday low of INR 1,145.20 before recovering sharply to touch an intraday high of INR 1,181.50. The day's high also marked a fresh 52-week high for the stock. The previous closing price was INR 1,153.00, while the volume-weighted average price (VWAP) stood at INR 1,173.82.
Trading Activity and Market Snapshot
Approximately 7.66 lakh shares were traded during the session, generating a traded value of around INR 89.95 crore. The order book reflected 41.47% buy quantity against 58.53% sell quantity, indicating relatively higher sell orders despite the stock trading in positive territory.
Zydus Lifesciences commanded a total market capitalisation of INR 1.16 lakh crore, while its free-float market capitalisation stood at INR 28,894.76 crore. The company is a constituent of the Nifty Next 50 index and operates in the pharmaceutical sector.
Stock Performance Across Timeframes
Zydus Lifesciences has delivered gains across all major investment horizons. The stock has risen 5.12% over the past week and 7.21% over the last month, outperforming the Nifty Next 50, which returned -0.41% and 4.10%, respectively.
On a year-to-date basis, the stock has advanced 27.42%, compared with the benchmark index's gain of 3.06%.
Over the past year, Zydus Lifesciences has gained 18.59%, while the Nifty Next 50 has returned 4.49%. The stock has also delivered returns of 100.26% over three years and 84.30% over five years.
Source: Analysis by Kalkine
March 2026 Quarter Financial Results
For the quarter ended March 31, 2026, Zydus Lifesciences reported unaudited consolidated total income of INR 7,72,120 lakh. Consolidated profit before tax stood at INR 1,65,970 lakh, while consolidated net profit was INR 1,34,100 lakh. Consolidated earnings per share (EPS) came in at INR 12.65.
On a standalone basis, total income stood at INR 4,23,600 lakh. Profit before tax was INR 2,11,100 lakh, while net profit reached INR 1,72,200 lakh. Standalone EPS for the quarter stood at INR 17.11. The company released its unaudited standalone and consolidated financial results on May 19, 2026.
Valuation and Trading Metrics
Zydus Lifesciences is trading at a symbol P/E ratio of 22.88, while its adjusted P/E stands at 21.32. The stock has traded within a 52-week range of INR 835.50 to INR 1,181.50, with the latest session establishing a fresh 52-week high.
Daily volatility stands at 1.50%, while annualised volatility is 28.66%. The applicable margin rate is 12.94%, and deliverable quantity accounted for 53.20% of traded volume.
Key Risks
- Regulatory inspections could affect manufacturing operations.
- Pricing pressure may impact profitability in export markets.
- Currency fluctuations could influence overseas earnings.
- Generic competition may affect product sales and margins.
Summary
Zydus Lifesciences shares gained more than 1% in early trade on July 8, touching a fresh 52-week high of INR 1,181.50. The stock has outperformed the Nifty Next 50 across short- and long-term periods, including year-to-date returns. The company also reported unaudited standalone and consolidated financial results for the March 2026 quarter, reflecting profitability across both reporting segments.
FAQs
Q: What was Zydus Lifesciences' share price on July 8, 2026?
A: The stock traded at INR 1,167.50, up 1.26% from the previous closing price during the morning session.
Q: Why is Zydus Lifesciences' 52-week high significant?
A: The stock reached a fresh 52-week high of INR 1,181.50, marking its highest trading level over the past year.
Q: What was Zydus Lifesciences' consolidated EPS for the March 2026 quarter?
A: The company reported consolidated earnings per share of INR 12.65 for the quarter ended March 31, 2026.